Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy.
Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy.
复制标题
一线紫杉醇化疗期间转移性乳腺癌生存的预后因素。
作者：
B. Nisman;V. Barak;A. Hubert;L. Kaduri;O. Lyass;M. Baras;T. Peretz
对54例一线紫杉醇化疗的转移性乳腺癌患者的各种人口统计学、临床和实验室特征的预后价值进行了研究。作为单药治疗，紫杉醇（175 mg/m2）每三周输注3小时。总有效率为30%。随访时间3 ~ 65个月（中位17个月）。最重要的治疗前生存预后因素是血红蛋白（相对风险-2.26; p = 0.02）和血清乳酸脱氢酶（RR-1.81; p = 0.04）水平。生存率与反应类型有很强的相关性。应答者的中位生存期是疾病进展患者的5倍（分别为30.2个月和5.7个月）。一线紫杉醇治疗后，肿瘤反应的估计值成为生存率的主要预测因素（RR-12.3; p < 0.0001）。
The prognostic value of various demographic, clinical and laboratory characteristics was investigated in 54 patients with metastatic breast cancer during first-line paclitaxel chemotherapy. As a single-agent treatment, paclitaxel (175 mg/m2) was given by 3-hour infusion every three weeks. The overall response rate was 30%. The follow-up ranged from 3 to 65 months (median 17 months). The most important pretreatment prognostic factors for survival were found to be hemoglobin (Relative Risk-2.26; p = 0.02) and serum lactic dehydrogenase (RR-1.81; p = 0.04) levels. The survival showed a strong association to the type of response. The median survival for responders was 5-fold greater than for patients with progressive disease (30.2 months and 5.7 months, respectively). Following the first-line paclitaxel treatment the estimates of tumor response became the major predictor of survival (RR-12.3; p < 0.0001).